摘要
FMS样酪氨酸激酶3(FMS-like tyrosine ki-nase 3,FLT3)基因突变在急性髓系白血病(AML)中发生率最高,且与不良预后相关。针对FLT3突变已经开发了多种靶向抑制剂,且取得了较好的临床疗效。但随之出现的耐药为FLT3靶向治疗AML带来新的挑战。本文将对FLT3突变在AML中的病理和预后作用、目前常用FLT3抑制剂(Ⅰ型和Ⅱ型)的研究进展、FLT3抑制剂耐药的机制及如何克服作一综述。
The FMS-like tyrosine kinase 3(FLT3)gene mutation is the most common genetic muta-tion in acute myeloid leukemia(AML)and is associ-ated with poor prognosis.Various targeted inhibi-tors have been developed for FLT3 mutations and have shown promising clinical efficacy.However,the emergence of resistance poses new challenges for targeted therapy in AML.This article provides an overview of the pathological and prognostic role of FLT3 mutations in AML,the current research progress on commonly used FLT3 inhibitors(type I and type II),the mechanisms of FLT3 inhibitor resis-tance,and strategies for overcoming resistance.
作者
吴庭恺
任崇崇
张婉婉
刘蓓
WU Tingkai;REN Chongchong;ZHANG Wanwan;LIU Bei(The First Clinical Medical School,Lanzhou University,Lanzhou 730000,Gansu,China;Department of Hematology,the First Hosptial of Lanzhou University,Lanzhou 730000,Gansu,China)
出处
《中国临床药理学与治疗学》
CAS
CSCD
北大核心
2024年第1期90-98,共9页
Chinese Journal of Clinical Pharmacology and Therapeutics
基金
甘肃省自然科学基金(18JR3RA356)。
